NEW YORK (GenomeWeb) – Finnish bioinformatics firm Euformatics announced today that it has received CE Marking for omnomicsNGS, a tool that helps labs interpret genetic variants and make clinical decisions.
The tool can help determine whether individual variants can have an effect on a patient's disease risk, or response to drugs or treatment, the company said. It performs variant annotation using the most recent disease-specific translational research and user-provided knowledge.
Euformatics launched the omnomicsQ, a management system for NGS workflows, in April 2015. The system lets users lay out quality metrics, draw up plans that determine the standards that are needed for NGS projects, and define tests that determine if a project conforms to the quality specifications laid out in the quality management plan. It's also the only quality management software that allows diagnostic laboratories to follow CAP or EuroGentest guidelines, the company said.